{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:47:28Z","timestamp":1767797248194,"version":"3.49.0"},"reference-count":38,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,12,10]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the prevalence of comorbidities among Middle Eastern patients with AF and their impact on clinical outcomes are scarce. This study aimed to assess the impact of comorbidities in a Middle Eastern population with AF treated with contemporary anticoagulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Patients from 20 hospitals and 30 outpatient cardiology clinics across Jordan were enrolled from May 2019 through October 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>2020 consecutive patients were enrolled. 117 of them were lost to follow-up, and 1903 had available data for analysis. Of the total, 1096 (54.3%) patients were women, and 924 (45.7%) were men. Eligible patients were 18 years of age or above, had a confirmed AF diagnosis and provided informed consent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcomes<\/jats:title>\n                    <jats:p>We are examining the outcomes of patients with AF, comparing those who have multimorbidities versus oligomorbidities. The primary outcomes were AF-related complications occurring within 1-year follow-up: major bleeding, non-major bleeding, stroke\/cerebrovascular accidents, systemic emboli and acute coronary syndrome. Secondary outcomes included causes of death among deceased patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the cohort, 1160 (57.4%) had two or less comorbidities (oligomorbidity group) and 860 (42.6%) had three or more comorbidities (multimorbidity group). Compared with the oligomorbidity group, the multimorbidity group had significantly higher rates of hypertension (97.9% vs 57.2%), diabetes mellitus type II (92.4% vs 7.3%), cardiovascular disease (100% vs 79.6%), chronic kidney disease (18.4% vs 1.8%) and chronic lung disease (7% vs 1%, p&lt;0.001 for all comparisons). Over the 1-year follow-up, the multimorbidity group experienced higher rates of hospitalisation (24% vs 16.9%, p&lt;0.001), all-cause death (21.4% vs 9.5%, p&lt;0.001) and cardiovascular death (11.8% vs 4.7%, p=0.002) than the oligomorbidity group. All-cause mortality in the multimorbid group was mostly related to hypertension with an OR of 5.5 (95% CI 2.07 to 14.73), history of stroke (OR 2.7, 95%\u2009CI1.85\u20134.03) and heart failure (OR 2.3, 95%\u2009CI 1.64 to 3.33). However, the use of warfarin (OR 0.6, 95%\u2009CI 0.38 to 0.82) and novel oral anticoagulants (OR 0.7, 95%\u2009CI 0.46 to 0.91) had protective effects from all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Middle Eastern patients with AF appear to exhibit a high burden of comorbidities. The results suggest the more comorbidities in these patients, the higher the rates of hospitalisation and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03917992\">NCT03917992<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-102661","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T05:15:13Z","timestamp":1766985313000},"page":"e102661","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study \u2013 A Prospective Cohort Study"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03917992","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03917992","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-3951","authenticated-orcid":false,"given":"Basil","family":"Abdin","sequence":"first","affiliation":[{"name":"School of Medicine, University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Abuqweider","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Al-Makassed Hospital, Jerusalem, Palestine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Alhaddad","sequence":"additional","affiliation":[{"name":"Cardiology Department, Jordan Hospital, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remin","family":"Shabaneh","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghayda\u2019","family":"Bader","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taima","family":"Bader","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abu-Shaban","sequence":"additional","affiliation":[{"name":"King Hussein Medical Center, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qais","family":"Salah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Quds University, Jerusalem, Palestine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Hammoudeh","sequence":"additional","affiliation":[{"name":"Istishari Hospital, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"key":"2026010703530321000_15.12.e102661.1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41569-022-00820-8","article-title":"Epidemiology and modifiable risk factors for atrial fibrillation","volume":"20","author":"Elliott","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026010703530321000_15.12.e102661.2","doi-asserted-by":"publisher","DOI":"10.1177\/1747493019897870"},{"key":"2026010703530321000_15.12.e102661.3","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317656"},{"key":"2026010703530321000_15.12.e102661.4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5455\/msm.2017.29.231-236","article-title":"The Impact of Risk Factors and Comorbidities on The Incidence of Atrial Fibrillation","volume":"29","author":"Naser","year":"2017","journal-title":"Mater Sociomed"},{"key":"2026010703530321000_15.12.e102661.5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/joa3.12555","article-title":"Revisiting the dynamic risk profile of cardiovascular\/non-cardiovascular multimorbidity in incident atrial fibrillation patients and five cardiovascular\/non-cardiovascular outcomes: A machine-learning approach","volume":"37","author":"Lip","year":"2021","journal-title":"J Arrhythm"},{"key":"2026010703530321000_15.12.e102661.6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/IJGM.S188524","article-title":"Atrial fibrillation: risk factors and comorbidities in a tertiary center in Jeddah, Saudi Arabia","volume":"12","author":"Mashat","year":"2019","journal-title":"Int J Gen Med"},{"key":"2026010703530321000_15.12.e102661.7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11071981","article-title":"Prognosis of Atrial Fibrillation with or without Comorbidities: Analysis of Younger Adults from a Nationwide Database","volume":"11","author":"Mertz","year":"2022","journal-title":"J Clin Med"},{"key":"2026010703530321000_15.12.e102661.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"2026010703530321000_15.12.e102661.9","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13498","article-title":"Integrated care and outcomes in patients with atrial fibrillation and comorbidities","volume":"51","author":"Proietti","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2026010703530321000_15.12.e102661.10","article-title":"Stroke prevention of atrial fibrillation: Improving geographic under-use of contemporary antithrombotic approaches remains a challenge","volume":"34","author":"Riesinger","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026010703530321000_15.12.e102661.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060274"},{"key":"2026010703530321000_15.12.e102661.12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/eurjcn\/zvad055","article-title":"Management of modifiable risk factors and comorbidities in atrial fibrillation: suggestions for improvement from a patient perspective","volume":"23","author":"Klaveb\u00e4ck","year":"2024","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2026010703530321000_15.12.e102661.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.11.008"},{"key":"2026010703530321000_15.12.e102661.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.07.013"},{"key":"2026010703530321000_15.12.e102661.15","article-title":"One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study","volume":"2022","author":"Hammoudeh","year":"2022","journal-title":"Int J Vasc Med"},{"key":"2026010703530321000_15.12.e102661.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44813-0","article-title":"Effect of multimorbidity on hypertension management","volume":"13","author":"Ji","year":"2023","journal-title":"Sci Rep"},{"key":"2026010703530321000_15.12.e102661.17","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2024-002641","article-title":"Multimorbidity in patients with atrial fibrillation","volume":"11","author":"Lobeek","year":"2024","journal-title":"Open Heart"},{"key":"2026010703530321000_15.12.e102661.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101860","article-title":"Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis","volume":"57","author":"Chowdhury","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026010703530321000_15.12.e102661.19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/jcdd12010006","article-title":"A New Risk Prediction Model for the Assessment of Myocardial Injury in Elderly Patients Undergoing Non-Elective Surgery","volume":"12","author":"Cicek","year":"2025","journal-title":"JCDD"},{"key":"2026010703530321000_15.12.e102661.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510350050036"},{"key":"2026010703530321000_15.12.e102661.21","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eun369"},{"key":"2026010703530321000_15.12.e102661.22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311402"},{"key":"2026010703530321000_15.12.e102661.23","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57060605","article-title":"Prevalence, Epidemiological Characteristics, and Pharmacotherapy of Coronary Artery Disease among Patients with Atrial Fibrillation: Data from Jo-Fib Study","volume":"57","author":"Al-Makhamreh","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2026010703530321000_15.12.e102661.24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1570161115666170414120532","article-title":"Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots","volume":"16","author":"Tsioufis","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"2026010703530321000_15.12.e102661.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61774-8"},{"key":"2026010703530321000_15.12.e102661.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.04.012"},{"key":"2026010703530321000_15.12.e102661.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01318-2","article-title":"Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study","volume":"20","author":"Gumprecht","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026010703530321000_15.12.e102661.28","first-page":"143","article-title":"Association of Atrial Fibrillation with Diabetes Mellitus, High Risk Comorbidities","volume":"17","author":"Gherasim","year":"2022","journal-title":"Maedica (Buchar)"},{"key":"2026010703530321000_15.12.e102661.29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jch.13768","article-title":"The effects of hypertension and diabetes on new-onset chronic kidney disease: A prospective cohort study","volume":"22","author":"Wang","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026010703530321000_15.12.e102661.30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.002097","article-title":"Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients","volume":"1","author":"Nelson","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"2026010703530321000_15.12.e102661.31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2022.05.044","article-title":"Association between comorbidities and left and right atrial dysfunction in patients with paroxysmal atrial fibrillation: Analysis of AF-RISK","volume":"360","author":"van Mourik","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026010703530321000_15.12.e102661.32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv163"},{"key":"2026010703530321000_15.12.e102661.33","doi-asserted-by":"crossref","DOI":"10.3390\/healthcare9070830","article-title":"Comorbidities Associated with One-Year Mortality in Patients with Atrial Fibrillation and Heart Failure","volume":"9","author":"Horodinschi","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"2026010703530321000_15.12.e102661.34","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1253\/circj.CJ-24-0630","article-title":"Predicting Short-Term Mortality in Patients With Acute Pulmonary Embolism With Deep Learning","volume":"89","author":"Cicek","year":"2025","journal-title":"Circ J"},{"key":"2026010703530321000_15.12.e102661.35","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.27.10.1765"},{"key":"2026010703530321000_15.12.e102661.36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/clc.20826","article-title":"Sinus rhythm restoration and treatment success: insight from recent clinical trials","volume":"34","author":"Saliba","year":"2011","journal-title":"Clin Cardiol"},{"key":"2026010703530321000_15.12.e102661.37","doi-asserted-by":"crossref","unstructured":"Rasmussen PV , Hansen ML , Gislason G , et al . P4774Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study. Eur Heart J 2019;40. doi:10.1093\/eurheartj\/ehz745.1150","DOI":"10.1093\/eurheartj\/ehz745.1150"},{"key":"2026010703530321000_15.12.e102661.38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.055079"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-102661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:54:38Z","timestamp":1767786878000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-102661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,28]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-102661"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-102661","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}